Today: August 24, 2017, 8:56 am
  
Business

Cryptococcosis Market to receive overwhelming hike in Revenues by 2025 - Credence Research

PR-Inside.com: 2017-05-19 20:10:42
According to the latest market report published by Credence Research, Inc. “Cryptococcosis Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025” the global Cryptococcosis market was valued at US$ 4.51 Bn in 2016, and is expected to reach US$ 6.76 Bn by 2025, expanding at a CAGR of 4.5% from 2017 to 2025.

Browse the full report Cryptococcosis Market - Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at www.credenceresearch.com/report/cryptococcosis-market

Market Insights

Cryptococcosis is a potentially fatal fungal disease occurs due to Cryptococcus, major causes of cryptococcosis are infection by neoformans and gattii. Increase in prevalence of fatal fungal disease, availability of advance treatment options and last-stage HIV patients developing the disease are driving the growth of Cryptococcosis market worldwide. For the purpose of study, global Cryptococcosis market is segmented on the basis of treatment type such as Amphotericin B, Flucytosine, Fluconazole and other treatment options. It is observed that, in the base year 2016, Flucytosine was major revenue contributing segment because it generally given as first line treatment in combination with other antifungal medications and higher adherence to Flucytosine treatment are influencing the growth of Flucytosine market worldwide. Cryptococcosis market is currently dominated by North America, United States observed as largest revenue contributor, due to factors such as higher cost of medication, rising incidence of the fungal infections in endemic areas of North America and higher investments in R&D in development of Cryptococcosis medication are driving the market growth in North America. Middle East and Africa expected to show significant market growth during forecast period because higher number of HIV infected patients and increase in demand for cryptococcosis medication would further drive the market growth during forecast period. However, factor such as comparatively lower cost of treatment medication may negatively impact the growth of Cryptococcosis market in Middle East and Africa.

Market Competition Assessment:

The Cryptococcosis market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Abbott Laboratories, Alkopharma Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Janssen Biotech, Inc. (Johnson & Johnson), Novartis AG, Pfizer, Inc., Sigmapharm Laboratories LLC., Valeant Pharmaceuticals, Inc. and other.

Key Market Movements:

• Factors such as higher prevalence of cryptococcosis, increase in awareness for treatment, favorable reimbursement policies in some countries and high degree of R&D activity in development of Cryptococcosis medication are driving the growth of cryptococcosis market worldwide.

• Due to the higher number of unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment options would further influence the market growth of Cryptococcosis market globally.

• However, poor patient compliance to medication in some countries and adverse effects associated with the use of medication would negatively impact the growth of Cryptococcosis market globally.

Request Sample: www.credenceresearch.com/sample-request/58453

Blog: globalpharmaindustry.com/2017/05/08/cryptococcosis-market-suppos ..

About:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: www.credenceresearch.com

Press Information
Credence Research
105 N 1st ST #429, SAN JOSE,

CA 95103, United States

Robson Tolson
Manager
18003618290
email
www.credenceresearch.com

Published by
Hemendra Parmar
+91 7755981105
e-mail
www.acutemarketreports.com/



# 549 Words
Related Articles
More From The Author
Global Opioid Induced Constipation Drugs Market Size, [..]
According to a recently published report by Brisk Insights, the Global Opioid Induced Constipation (OIC) Drugs Market is expected [..]
Chronic Idiopathic Constipation (CIC) Drugs Market Size, [..]
According to a recently published report by Brisk Insights, the Global Chronic Idiopathic Constipation (CIC) Drug Market is [..]
Direct-to-consumer (DTC) Genetic Testing Market Size, Share [..]
According to a recently published report by Brisk Insights, the Global Direct-to-consumer Genetic Testing Market is expected to [..]
Global Antibacterial Drugs Market Size, Share and [..]
According to a recently published report by Brisk Insight, the Global Antibacterial Drugs Market is expected to grow at the [..]
Global Set-top Boxes Market Size, Share and [..]
According to a recently published report by Brisk Insights, the Global Set-top Boxes Market is expected to grow at the [..]
 
More From Business
Weifa ASA: mandatory notification of trade and [..]
Weifa ASA - mandatory notification of trade and disclosure of shareholding Reference is made to the announcement from Karo Pharma [..]
Weifa ASA: Karo Pharma AB announces a [..]
Karo Pharma AB announces a recommended voluntary cash offer to acquire all shares in Weifa ASA             · Cash [..]
SDRL - Seadrill Limited Announces First Quarter [..]
Highlights Revenue of $577 million  Operating loss of $100 million  EBITDA of $264 million  97% economic utilization Reported [..]
Karolinska Development - Interim Report (January-June 2017) [..]
STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 [..]
Leasinvest Real Estate SCA: Half-year financial report [..]
Highlights first half-year 2017 Redevelopments Montoyer 63 and Treesquare in Brussels and Strassen in Luxembourg on schedule The [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.